Mile­stones

The Top Employers Institute honors our company for the third year in succession with a “Global Top Employer” award. The certification also highlights the company’s commitment to employee wellbeing, work environment, as well as rewards and recognition.

The trial results reinforce the potential of spesolimab to prevent GPP (generalized pustular psoriasis) flares in adolescents and adults with GPP for up to 48 weeks.

LastMile aims to bridge the gap in access, availability, and awareness of animal healthcare solutions in hard-to-reach areas in Sub-Saharan Africa, while improving productivity and income generation, as well as ensuring food security and livelihood for the local communities.

The new high-tech facility will strengthen innovation power and development of biopharmaceuticals, accounting for approx. 50% of our research pipeline, as well as create more than 500 job opportunities.

The new plant will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases thus rapidly advancing new drug candidates from our vast research pipeline to clinical trials and ultimately to market approval.

Up to 40% of people who reached the highest two doses of survodutide achieved a weight loss of at least 20%; survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite.

The Jardiance® (empagliflozin) approval in chronic kidney disease adds to existing indications in type 2 diabetes and heart failure; these interconnected conditions affect over 1 billion people worldwide.

SENVELGO® (velagliflozin oral solution) is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus, making the treatment of this disease simple and convenient for both cats and cat owners.

The Science Based Targets initiative (SBTi) approves our 2030 emission reduction targets; it will monitor and report on our progress to deliver our science-based greenhouse gas (GHG) emission reduction targets. This validation underlines our commitment to aligning its efforts to tackle climate change and reduce global warming in line with the 2015 Paris Agreement.

This long-term strategic collaboration aims to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for people with serious eye diseases.

Phase II results demonstrate significant albuminuria (marker of kidney damage) reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor, was given on top of empagliflozin, suggesting additive efficacy.

This partnership aims to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). Currently there are no approved medicines for MASH and there is an urgent need for new effective treatment options that can prevent MASH progression and maintain and restore liver function.